Published in Cancer Weekly, September 5th, 2000
BZL holds the exclusive worldwide license to this technology from Cornell University. The issued patent claims monoclonal antibodies that bind to the extracellular domain of prostate specific membrane antigen (PSMAext.) on living cells as both therapeutic and diagnostic agents for prostate cancer. These monoclonal antibodies to the extracellular domain of PSMA may be used unmodified or as a targeting antibody for radioisotopes and/or cytotoxic drugs.
According to Dr. Neil...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.